We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
Cap. Flow
+$9.92M
Cap. Flow %
0.69%
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55
Avg Time Held Equity + Options
2.9 quarters
Top 10 Avg Time Held Equity + Options
4.7 quarters
Top 20 Avg Time Held Equity + Options
4.1 quarters
Avg Time Held Equity only
3.1 quarters
Top 10 Avg Time Held Equity only
4.7 quarters
Top 20 Avg Time Held Equity only
4.9 quarters

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$24.7M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.4M
4
STJ
St Jude Medical
STJ
+$16.6M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$41.5M
2
HUM icon
Humana
HUM
+$20.1M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
4
BAX icon
Baxter International
BAX
+$9.04M
5
XLRN
Acceleron Pharma
XLRN
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.68%
2 Miscellaneous 20.64%
3 Consumer Staples 0.52%
4 Consumer Discretionary 0.08%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SRPT icon
1
PUT
Sarepta Therapeutics
SRPT
$1.84B
$145M 10.07%
+7,619,300
New +$141M
2016 Q2
0 quarters
NBIX icon
2
Neurocrine Biosciences
NBIX
$14.4B
$127M 8.82%
2,797,967
+77,000
+3% +$3.55M
2013 Q2
12 quarters
TSRO
3
DELISTED
TESARO, Inc.
TSRO
$96.1M 6.66%
1,143,615
+44,956
+4% +$2M
2013 Q2
12 quarters
FOLD icon
4
DELISTED
Amicus Therapeutics
FOLD
$83.2M 5.77%
15,239,444
– –
2014 Q1
9 quarters
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.84B
$71.8M 4.98%
3,767,316
-65,812
-2% -$1.22M
2013 Q2
12 quarters
TVTX icon
6
Travere Therapeutics
TVTX
$4.9B
$58.4M 4.05%
3,279,380
+280,000
+9% +$4.53M
2014 Q1
9 quarters
MDVN
7
DELISTED
MEDIVATION, INC.
MDVN
$45.8M 3.18%
760,000
+420,000
+124% +$23.8M
2016 Q1
1 quarter
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
$36.6M 2.54%
2,207,668
+910,200
+70% +$18.4M
2015 Q3
3 quarters
ARAV
9
DELISTED
Aravive, Inc. Common Stock
ARAV
$31.4M 2.17%
472,626
– –
2014 Q1
9 quarters
NXTM
10
DELISTED
NxStage Medical Inc.
NXTM
$30M 2.08%
+1,382,410
New +$24.7M
2016 Q2
0 quarters
IOVA icon
11
Iovance Biotherapeutics
IOVA
$6.6B
$29.3M 2.03%
3,611,976
+824,720
+30% +$5.18M
2015 Q1
5 quarters
XNCR icon
12
Xencor
XNCR
$1.86B
$29M 2.01%
1,529,574
-275,210
-15% -$3.77M
2013 Q4
10 quarters
XBI icon
13
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$27M 1.87%
+500,000
New +$27.4M
2016 Q2
0 quarters
NVRO icon
14
DELISTED
NEVRO CORP.
NVRO
$26.9M 1.87%
365,229
+16,629
+5% +$1.13M
2014 Q4
6 quarters
CPXX
15
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$25.3M 1.75%
838,400
-261,600
-24% -$5.31M
2016 Q1
1 quarter
LJPC
16
DELISTED
La Jolla Pharmaceutical Company
LJPC
$21.3M 1.48%
1,332,815
+633,300
+91% +$11.4M
2014 Q3
7 quarters
XLRN
17
DELISTED
Acceleron Pharma
XLRN
$20.5M 1.42%
603,036
-200,000
-25% -$6.5M
2014 Q2
8 quarters
SRPT icon
18
CALL
Sarepta Therapeutics
SRPT
$1.84B
$18.7M 1.29%
979,200
+429,200
+78% +$7.95M
2014 Q3
7 quarters
STJ
19
DELISTED
St Jude Medical
STJ
$18.2M 1.26%
+233,000
New +$16.6M
2016 Q2
0 quarters
DBVT icon
20
DBV Technologies S.A. American Depositary Shares
DBVT
$600M
$17.8M 1.24%
54,670
+13,000
+31% +$4.21M
2015 Q2
4 quarters
QTNT
21
DELISTED
Quotient Limited Ordinary Shares
QTNT
$17.4M 1.21%
56,227
+1,500
+3% +$573K
2014 Q2
8 quarters
EVH icon
22
Evolent Health
EVH
$481M
$16.8M 1.16%
873,064
+254,134
+41% +$3.49M
2015 Q2
4 quarters
TLPH icon
23
Talphera
TLPH
$56.1M
$16.1M 1.12%
299,788
– –
2013 Q2
12 quarters
DERM icon
24
DELISTED
Dermira, Inc.
DERM
$13.5M 0.94%
462,000
-50,000
-10% -$1.38M
2014 Q4
6 quarters
VBIV icon
25
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$12.1M 0.84%
101,948
-6,731
-6% -$674K
2015 Q1
5 quarters
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q2 2016 filing shows 57 new, 37 increased, 31 reduced and 55 closed positions. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M. The largest sale was Allergan plc, an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
  • Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
  • Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
  • Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
  • Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
  • Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.